AUTHORS
Lei Zhao, MD, Yu Wu, MD2, Mengran Chen I, MD3, Jinjun Yang4, Hongbin Yu5
AFFILIATIONS
1 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
2 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
3 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
4 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
5 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
ABSTRACT
Abstract
Background: Monocytic differentiation is associated with reduced sensitivity to venetoclax plus hypomethylating agents (VEN+HMA) in acute myeloid leukemia (AML), but monocytic phenotypes are heterogeneous and incompletely predict clinical resistance. We investigated whether quantitative CD56/NCAM1 expression within separately defined leukemic compartments identifies a more specific VEN+HMA-resistant state than monocytic burden alone.
Methods: In this single-center retrospective study, archived Flow Cytometry Standard files were centrally reanalyzed from consecutive patients with AML who received a first VEN-based combination regimen at West China Hospital between April 3, 2020, and January 31, 2025. Abnormal blast and monocytic compartments were independently gated, and surface-marker median fluorescence intensity (MFI) was quantified within each compartment. Associations with composite complete remission (cCR; complete remission plus complete remission with incomplete hematologic recovery) and overall survival (OS) were evaluated separately for VEN+HMA and chemotherapy-containing VEN regimens. Multivariable logistic regression assessed independent response associations. Bulk RNA sequencing, public single-cell RNA-sequencing and patient-derived xenograft (PDX) datasets, and acquired VEN-resistant AML cell-line models provided orthogonal biological context.
Results: The cohort included 445 patients and 772 evaluable flow-cytometry samples, including 472 pre-VEN samples used for response analyses. Among evaluable patients, cCR occurred in 83/171 (48.5%) treated with VEN+HMA, 45/65 (69.2%) treated with VEN plus chemotherapy, and 125/181 (69.1%) treated with VEN plus HMA and chemotherapy. Because treatment allocation was nonrandom, all biomarker analyses were regimen-stratified. In VEN+HMA-treated samples, each 1-unit increase in log2-transformed CD56 MFI was associated with lower odds of cCR in blast (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.65-0.89) and monocytic compartments (OR, 0.76; 95% CI, 0.60-0.95), whereas monocytic fraction was not associated with cCR (OR, 0.99; 95% CI, 0.96-1.03). Neither blast nor monocytic CD56 was associated with cCR after chemotherapy-containing VEN regimens. Among newly diagnosed patients treated with VEN+HMA, blast CD56 remained independently associated with lower odds of cCR after adjustment for monocytic-associated phenotype, secondary or therapy-related AML, 2022 European LeukemiaNet adverse-risk status, and age (OR, 0.66; 95% CI, 0.52-0.83; P<0.001). High blast CD56 was associated with shorter OS in newly diagnosed disease (median, 5.91 vs 17.48 months; P<0.001), and high monocytic CD56 showed a concordant association (5.19 vs 17.08 months; P=0.004). Bulk RNA sequencing showed higher NCAM1 expression in VEN+HMA nonresponders. In paired samples, NCAM1 transcript abundance correlated with CD56 MFI in blast (r=0.681; P<0.001) and monocytic compartments (r=0.553; P=0.014). NCAM1-high samples exhibited immune-inflammatory, T/NK-cell regulatory, adhesion, and niche-related transcriptional features. Public single-cell analyses showed minimal NCAM1 expression in normal adult myeloid compartments, predominant enrichment in monocytic regions of newly diagnosed AML, and redistribution toward immature myeloid and progenitor regions in chemotherapy-relapsed AML. Public PDX data and paired cell-line models further supported enrichment or upregulation of NCAM1/CD56 in selected VEN-resistant states.
Conclusions: Compartment-resolved quantitative flow cytometry identifies CD56/NCAM1-high AML as a treatment-context-dependent state associated with resistance and inferior survival after VEN+HMA. CD56/NCAM1 refines the monocytic-resistance model by identifying an adverse antigenic state enriched in, but not confined to, monocytic compartments. Prospective external validation and assay standardization are required before clinical implementation.
DISCLOSURES
Lei Zhao, MD: No relevant conflicts of interest to declare.